Resmetirom Patent Expiration
Resmetirom is Used for treating adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. It was first introduced by Madrigal Pharmaceuticals Inc
Resmetirom Patents
Given below is the list of patents protecting Resmetirom, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezdiffra | US10376517 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US11564926 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US11986481 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US9266861 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | Sep 17, 2033 | Madrigal |
| Rezdiffra | US7452882 | Thyroid hormone analogs | Sep 12, 2026 | Madrigal |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Resmetirom's patents.
Latest Legal Activities on Resmetirom's Patents
Given below is the list recent legal activities going on the following patents of Resmetirom.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 26 Jun, 2024 | US7452882 |
| Email Notification Critical | 26 Jun, 2024 | US7452882 |
| Initial letter Re: PTE Application to regulating agency | 07 May, 2024 | US7452882 |
| Initial letter Re: PTE Application to regulating agency | 07 May, 2024 | US9266861 |
| Requirement for information sent under 37 CFR 1.750 | 07 May, 2024 | US7452882 |
| Patent Term Extension Application under 35 USC 156 Filed | 02 May, 2024 | US7452882 |
| Patent Term Extension Application under 35 USC 156 Filed | 02 May, 2024 | US9266861 |
| Email Notification Critical | 17 Apr, 2024 | US7452882 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Apr, 2024 | US7452882 |
| Change in Power of Attorney (May Include Associate POA) Critical | 11 Apr, 2024 | US9266861 |
Resmetirom's Family Patents
